Your session is about to expire
← Back to Search
Pembrolizumab for Non-Small Cell Lung Cancer
Study Summary
This trial is studying ramucirumab and pembrolizumab to see how well they work compared to standard of care in treating patients with non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have never had an organ transplant requiring immunosuppressives.My cancer does not have specific genetic changes or has progressed despite treatment.I haven't had a blood clot in the last 3 months, or if I have, I've been on a stable blood thinner dose for over 3 months.I have chronic hepatitis B but it's undetectable with treatment.I do not have severe liver problems or complications from liver disease.I am fully active or restricted in physically strenuous activity but can do light work.I haven't had a heart attack or stroke in the last 6 months.I have not had severe side effects from previous immunotherapy.I haven't had a serious wound, ulcer, or bone fracture in the last 28 days.I haven't taken high-dose steroids or immunosuppressants in the last week.I haven't taken aspirin, ibuprofen, or similar drugs in the last 7 days.My liver enzymes are within the normal range.I have HIV, am on effective treatment, and my viral load is undetectable.I haven't had chemotherapy, immunotherapy, or experimental drugs in the last 3 weeks.I have not had severe gastrointestinal bleeding in the last 3 months.I do not have symptoms of active tuberculosis.My blood pressure has been under control with medication for over 4 weeks.I haven't needed treatment for an autoimmune disease in the last 2 years.I have never needed steroids for lung inflammation not caused by an infection.I haven't had any serious gut issues like perforations or abnormal connections in the last 6 months.I do not have severe heart disease, recent heart attacks, or uncontrolled heart rhythm problems.I do not have acute hepatitis or any active infections.I had hepatitis C but am cured, or I'm being treated with no detectable virus.I have not had major surgery in the last 28 days or a device placed under my skin in the last 7 days.I haven't coughed up a significant amount of blood recently and my cancer hasn't invaded major blood vessels.I have no cancer history except for certain skin cancers, early-stage cancers in remission, or any cancer I've been free from for 5 years.I can safely participate in the study despite having decision-making challenges.I have had a brain scan within the last 42 days.I've had one round of specific immune therapy for over 84 days.I have not had a live vaccine in the last 4 weeks.I am not planning to receive any other cancer treatments while on this study.My blood clotting time is within 5 seconds of the normal range, not counting any blood thinners I might be on.I switched from warfarin to low molecular weight heparin and my blood clotting levels have been stable for 14 days.I haven't taken nitrosoureas or mitomycin-c in the last 42 days.I had a physical exam within the last 28 days.My kidney function, measured by creatinine levels or clearance, is within normal limits.I haven't had radiotherapy in the last 14 days or lung radiation over 30 Gy in the past 6 months.
- Group 1: Arm B (ramucirumab, pembrolizumab)
- Group 2: Arm A (docetaxel, gemcitabine, ramucirumab, pemetrexed)
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are some of the potential side effects associated with Ramucirumab?
"Because there is only some data supporting its safety, Ramucirumab was given a score of 2."
Are there any current vacancies for this research program?
"No, this particular trial is not currently looking for new participants. Although the listing on clinicaltrials.gov says it was most recently updated on October 8th, 2021, recruitment for this study actually ended long ago on May 28th, 2019. There are however other 4,860 studies that patients can take part in."
How many individuals are enrolled in this clinical trial?
"This research is no longer enrolling patients. The study was first advertised on May 28th, 2019 and received its last update on October 8th, 2021. If you are interested in other studies, there are 2998 clinical trials actively recruiting for patients with non-small cell lung carcinoma and 1862 studies for Ramucirumab that still need participants."
Could you direct me to other scientific research on Ramucirumab's efficacy?
"As of right now, there are 1862 different ongoing studies that include Ramucirumab with 410 trials in the third stage. Many clinical trials for Ramucirumab take place in Shanghai, but there are 78280 locations researching this medication."
For what medical conditions is Ramucirumab commonly given to patients?
"Ramucirumab is most often used to treat malignant neoplasms, however it can also be effective for treating microsatellite instability high, non-small cell lung carcinoma, and unresectable melanoma."
Are there different research facilities conducting this trial in North America?
"One hundred sites are running this clinical trial presently. They are situated in Goshen, Sioux Falls and Richmond among other cities. If you choose to participate in the trial, it would be beneficial to select a site closest to your location to reduce travel time commitments."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger